EMA Authorised: Pravafenix (fenofibrate;pravastatin) — Laboratoires SMB S.A.

View source ↗

Summary

The EMA authorised Pravafenix, a fixed-dose combination of fenofibrate and pravastatin, for dyslipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• Pravafenix

Snippet

Status: Authorised. Therapeutic area: Dyslipidemias. MAH: Laboratoires SMB S.A.. Decision date: 21/10/2024